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Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance in psy- 
choses, mainly schizophrenia spectrum disorders. We aimed to summarize available evidence 
of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder 
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(BD) and/or Schizoaffective Disorder (SAD). We searched six databases from inception to 28- 
March-2018, using the strategy: long-acting antipsychotics AND (bipolar disorder OR schizoaf- 
fective disorder OR mania OR manic OR bipolar depression). We included peer-reviewed 
double-blind comparisons of LAIs for any clinical outcome occurrence in BD, or open mir- 
ror studies with same prospective as retrospective assessment periods. We excluded studies 
reporting on mixed schizophrenia/SAD populations without reporting results separately. The 
pooled records amounted to 642. After duplicate removal and inclusion/exclusion criteria ap- 
plication, we included 15 studies, 6 double-blind and 9 open, 13 assessing BD and 2 SAD. De- 
pot neuroleptics prevented manic, but not depressive recurrences and may worsen depressive 
symptoms. Risperidone long-acting injectable was found to be effective in protecting from any 
mood/manic symptom compared to placebo, but not from depressive recurrences. Add-on or 
monotherapy paliperidone palmitate in SAD patients protected from psychotic, depressive, and 
manic symptoms. In patients with BD-I with a manic episode at study enrolment, aripiprazole 
monohydrate significantly delayed time to recurrence of manic episodes without inducing de- 
pressive episodes. LAIs are effective and well-tolerated maintenance treatments for BD and 
SAD. They showed better efficacy in preventing mania than depression. LAIs may be first-line 
for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems. 











































































Bipolar Disorder (BD) is a severe, recurrent and disabling
mood disorder characterised by manic, hypomanic or mixed
episodes, and alternating episodes of depression that af-
fects approximately 2% of worldwide population ( Grande
et al., 2016 ). Affective episodes are recurrent and com-
monly associated with unfavorable outcomes, including
poorer cognitive performance and greater number of hos-
pitalizations ( Vieta et al., 2018 ). BD is typically associated
with high mortality due mostly to cardiovascular diseases
and an increased risk of suicide ( Kendall et al., 2014; Kishi
et al., 2016; Vieta et al., 2018 ). Moreover, BD is often as-
sociated with persistent symptoms leading to social and
functional impairment ( Martinez-Aran et al., 2009; Borto-
lato et al., 2015; Solé et al., 2018 ). Due to the chronic
nature of the disorder and the negative consequences of
unremitted or recurrent symptoms, BD requires long-term
maintenance therapy to prevent future mood episodes as
the primary goal of treatment after treating an acute af-
fective episode. Despite lithium remains the gold standard
prophylactic treatment for BD ( Nivoli et al., 2010 ), patients
may not accept lithium due to various reasons including
monitoring requirement, side effects or poor adherence to
treatment ( Murru et al., 2012, 2013 ). Thus, many patients
require alternative prophylactic treatment for BD. Multiple
studies and most BD treatment guidelines ( Derry and Moore,
2007; Goodwin GM and Consensus Group of the British Asso-
ciation for Psychopharmacology, 2009; Grunze et al., 2013;
National Collaborating Centre for Mental Health (UK), 2018;
Yatham et al., 2018 ) recommend the use of oral second-
generation antipsychotics (SGAs) as a long-term option for
BD and many SGAs have official European Medical Agency
(EMA) approval for this indication. 
Similarly, schizoaffective disorder (SAD) is a chronic and
severe illness consisting on the concurrent presentation of
symptoms of schizophrenia and affective disorders (depres-
sion and/or mania) ( Murru et al., 2016 ). Actually, there is
a still unresolved debate on nosological distinctions amongPlease cite this article as: I. Pacchiarotti, J. Tiihonen and G.D. Ko
maintenance treatment of bipolar and schizoaffective disorders: A 
//doi.org/10.1016/j.euroneuro.2019.02.003 schizoaffective disorder (SAD), BD-I with psychotic features
and schizophrenia (SZ) ( Tondo et al., 2016 ). 
Adherence to medication is essential for BD and SAD
patients to respond satisfactorily to treatment. Nonethe-
less, the frequency of nonadherence in BD and SAD pa-
tients bipolar type is estimated to range between 10% and
60% (9,10,18) even during euthymic periods ( Colom et al.,
2000 ). Nonadherence increases the risk of relapse and sui-
cide ( Samalin et al., 2014 ) as well as the risk of rehospi-
talization ( Gigante et al., 2012 ). It should be stressed that
despite patients’ will to receive LAI treatment, this type
of treatment is still less used in patients discharged af-
ter hospitalization for a psychotic episode ( Hamann et al.,
2014 ), even if their long-term safety has been demonstrated
( Lindenmayer et al., 2007 ). 
Long-acting injectable (LAIs) antipsychotics, including
first-generation depot antipsychotics (FGDAs) and second-
generation depot antipsychotics (SGDAs) may improve
treatment adherence in patients with psychiatric illness re-
quiring long-term maintenance treatment ( Gigante et al.,
2012; Llorca et al., 2013 ). LAIs have been shown to de-
crease the rate of relapse and hospitalization in patients
with schizophrenia ( Correll et al., 2016 ). The use of LAIs
in the maintenance treatment of BD and SAD has raised
interest for improving adherence and reducing the risk
of relapse ( Gigante et al., 2012; Samalin et al., 2014;
Kishi et al., 2016 ). In a recent, large population-based ob-
servational cohort effectiveness study ( N = 18,018) based
on the Finish registry of the whole population of Finland
( Lähteenvuo et al., 2018 ), the most effective treatments
to prevent re-hospitalization in BD patients were lithium
and LAIs, with 30% of rehospitalization risk reduction with
LAIs compared to the same medications in oral formula-
tions. To date, FDA has approved the use of risperidone-
LAI (RIS-LAI) as both monotherapy and as adjunct therapy
to lithium and valproate for the maintenance treatment
of BD-I. Recently, FDA has approved aripiprazole monohy-
drate extended-release injectable suspension (Ari-M) for
the maintenance monotherapy treatment of BD-I. RIS-LAItzalidis et al., Long-acting injectable antipsychotics (LAIs) for 
systematic review, European Neuropsychopharmacology, https: 
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nd recently paliperidone palmitate (Pal-P) have received 
MA indication for SAD disorder. On the contrary, no LAI has
urrent EMA indication for BD. Although FGDAs have been 
tudied in BD, they have not been approved for use in this
isorder ( Gigante et al., 2012 ). 
To summarize the available evidence, we conducted a 
ystematic review of studies comparing the efficacy and 
afety of first- and second-generation depot antipsychotics 
FGDAs and SGDAs, respectively) to placebo (PBO) or oral 
edications for BD and SAD. We decided to include in this
eview also SAD due to the similarities in acute and long-
erm need for treatments aimed at manic, mixed, depres- 
ive polarities, both psychotic and nonpsychotic, that jus- 
ify a conceptual framework of continuity across these two 
onditions ( Murru et al., 2016; Argolo et al., 2018 ). 
. Procedures 
his review has been conducted according to the PRISMA 
 P referred R eporting I tems for S ystematic Reviews and
 eta- A nalyses) statement ( Moher et al., 2009 ). Search
ethods and Results are highlighted in Fig. 1 . 
.1. Literature search 
e systematically searched the MED- 
INE/PubMed/Index Medicus, Cochrane Library, CINHAL, 
sycINFO/PsycARTICLES, clinicaltrials.gov, and Scopus 
atabases from any time to 28 March 2018, cross-checking 
he obtained references. The systematic search was per- 
ormed by two blind independent research teams (led by IP 
nd GDK), searching as follows: 
• MEDLINE/Pubmed/Index Medicus: authors used the fol- 
lowing search strategy: (depot OR once-monthly OR 3- 
month ∗ OR long-acting OR LAI[ti] OR LAIs[ti] OR mono- 
hydrate OR lauroxil OR palmitate OR pamoate OR 
microsphere ∗ OR dodecanoate OR decanoate OR enan- 
thate OR oenanthate OR acetate OR consta OR main- 
tena OR zypadhera OR xeplion OR sustenna OR trinza) 
AND (aripiprazole OR olanzapine OR risperidone OR 
paliperidone OR risperdal OR 9-OH-risperidone OR 9- 
hydroxyrisperidone OR haloperidol OR fluphenazine OR 
flupentixol OR flupenthixol OR zuclopenthixol OR pipoth- 
iazine) AND (bipolar disorder OR bipolar depression OR 
mania OR manic OR schizoaffective) that produced 374 
records. Of them, duplicates were 0, and selected for 
analysis 13. 
• For the Cochrane library we used the same search 
strategy, save for the use of square brackets, that the
database’s system does not accept; the search produced 
144 records, one of which unlocalisable. It added no in-
cludible record to the PubMed search. 
• With the other databases we performed the same search 
as for PubMed. CINHAL yielded 92 records. 
• PsycINFO/PsycARTICLES yielded 365 records. 
• Scopus produced 37 records. 
• For the https://clinicaltrials.gov/ database, keywords 
were: long-acting antipsychotics AND bipolar disorder 
OR schizoaffective disorder and produced 29 records. Of Please cite this article as: I. Pacchiarotti, J. Tiihonen and G.D. Ko
maintenance treatment of bipolar and schizoaffective disorders: A 
//doi.org/10.1016/j.euroneuro.2019.02.003 all databases used and the additional 15 records that
were identified through other sources/reference lists, 
none added an includible article to the pool of records
identified by and selected from PubMed. 
.2. Study selection 
e included longitudinal studies of the effect of LAIs in the
reatment of patients with BD and SAD. Studies could be
xperimental (randomized clinical trials (RCT), quasi-RCTs, 
onRCTs), quasi-experimental (controlled before and after 
tudies, interrupted time series), and observational (cohort, 
ase-control, registry studies). We excluded animal studies, 
nd studies resulting from databases but not being relevant
s to the effects of the administration of LAI antipsychotics
n patients with BD or SAD. Excluded were also studies on
he effects of LAIs on mixed schizophrenia/schizoaffective 
isorder patients without reporting results separately. Meta- 
nalyses and reviews were used as evidence to support in-
ormation that could not be drawn from individual studies.
pen studies, unless they had a mirror design with a retro-
pective period equal to the longitudinal prospective one, 
ase reports or series, pharmacoeconomy studies not pro- 
iding clinical outcomes, letters to the editor, author re-
ponses to criticisms, opinion papers, editorials, studies fo- 
using only on biomarkers, like genetic investigations and 
rain imaging, pharmacokinetic studies, technical studies 
ocusing on types of formulations or study designs, were ex-
luded. Congress Abstracts, despite not being subjected to 
eer reviewing, were considered if they provided sufficient 
ata for analysis and they were not subsequently published
n regular papers. 
For this review, we filled-in the PICO worksheet ( Miller,
001 ), the AMSTAR form ( Shea et al., 2017 ), and the PRISMA
hecklist ( Moher et al., 2009 ), which we provide as an on-
ine Supplementary file. We assessed the quality of included
rials with Jadad’s et al. (1996) scale for the evaluation of
andomized control trials and the strength of our recom-
endations with the National Health and Medical Research 
ouncil (NHMRC) of the Australian Government’s (2009) 
HMRC levels of evidence and grades for recommendations 
or developers of guidelines. Risk of bias was addressed with
aking into account the Cochrane Risk of Bias Tool ( Higgins
nd Green, 2011 ), classifying each study according to a high,
ow, unclear category for the selection, reporting, perfor- 
ance, detection, attrition, and other dimensions, which 
hen affected the global quality of the paper. 
. Results 
.1. Systematic search results 
he pooled records amounted to 640 Records ( Fig. 1 ). Ex-
luded were: 114 Reviews, 113 NBSA, 77 No LAI, 65 Open
open design-no mirror), 130 Case (reports/series), 0 In- 
deq (inadequate design or outcomes), 33 E/O (editori- 
ls/opinion papers), 13 PhEc (Pharmacoeconomic studies), 
4 Surveys, 1 Biotech (biotechnologies, laboratory), 15 PhK 
pharmacokinetics), 12 BM/Gen (biomarkers, brain imaging, tzalidis et al., Long-acting injectable antipsychotics (LAIs) for 
systematic review, European Neuropsychopharmacology, https: 
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Fig. 1 PRISMA flow diagram and results of our literature search, including reasons for exclusion and typology of included studies. 




































or genetics), 3 Technical, 3 Animal/Cell (studies on nonhu-
mans or on isolated cell tissues), 1 was a secondary analysis
of the data of another study that had changed the primary
outcome to a part of the primary outcome of the other (i.e.,
time to hospitalization instead of time to recurrence, which
was defined in part also by hospitalization) and 30 Same (re-
porting data elsewhere published better). 1 was not possible
to localize. This left 15 records to include ( Fig. 1 ). We in-
cluded 6 double-blind studies and 9 open studies. 13 studies
assessed BD and 2 SAD. One trial tested aripiprazole mono-
hydrate once monthly (double-blind, BD); 2 trials assessed
the use of flupenthixol depot (1 double-blind, 1 open, BD); 1
trial tested paliperidone palmitate (double-blind, SAD); 11
trials assessed RIS-LAI (8 open-3 double-blind, 10 BD-1 SAD).
The details of each study are reported in Table 1 . 
Most studies were of good to satisfactory quality of ev-
idence, but none was excellent, despite some studies had
included large samples ( Table 1 ). Reasons varied, with all
multisite studies not addressing intersite variability issues,
high rate of attrition bias, not clearly disclosed method of
randomization, small samples, and possible sponsor bias.Please cite this article as: I. Pacchiarotti, J. Tiihonen and G.D. Ko
maintenance treatment of bipolar and schizoaffective disorders: A 
//doi.org/10.1016/j.euroneuro.2019.02.003 Hence, the total strength of recommendations of this re-
view according to the National Health and Medical Research
Council (NHMRC) (2009) is from satisfactory to good. 
3.2. Content results 
3.2.1. First-generation depot antipsychotics (FGDA) 
Two studies have been included regarding the use of flu-
penthixol depot in BD patients as alternative to lithium.
The first ( Ahlfors et al., 1981 ) was a non-blind, randomized
study with flupenthixol decanoate vs . lithium in 33 BD pa-
tients who had experienced at least three manic or depres-
sive episodes during the last 5 years before the enrolment.
The results showed no differences in terms of number of
episodes per year and in time spent ill between the two
groups. Also comparing the 5 years pre-trial, neither flu-
penthixol nor lithium showed significant prophylactic effect
against mood episodes. In the second RCT study ( Esparon
et al., 1986 ), 15 patients were randomized to flupenthixol
20 mg/month or PBO as adjunctive treatment to lithium. Notzalidis et al., Long-acting injectable antipsychotics (LAIs) for 
systematic review, European Neuropsychopharmacology, https: 
LAIs in bipolar and schizoaffective disorders 5 
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Table 1 Summary of included studies in reverse chronological order, their quality/risk of bias assessment, and their typology. 
Studies by first 
author and 
date in reverse 
order 
Study design Population, n 
(sites; sp. Y/N) 
Duration Drug Main outcomes Quality 
(includes 
bias) 
Hsieh et al. 
(2017) 
Open RIS-LAI mirror 









12 months RIS-LAI (mean 
dose:24.6 
mg/2weeks) as 
add-on to TAU 
during 1 year 
( n = 287) 
- The prevalence of 
concomitant use of TAU 
decreased from the 
pre-RIS-LAI period to the 
post-RIS-LAI period 
- RIS-LAI use decreased 
emergency room (ER) visits, 
hospital admissions, length 
of hospital stay, and 
non-medication costs 
- RIS-LAI use decreased the 
number of change-in-mood 




et al. (2017) 
DB Ari-M vs . PBO 
withdrawal surv 
(BD-I) 
266 (103, 7 
countries in 3 
continents; Y) 
52 weeks Ari-M (400 mg/1 
month) ( n = 133 
completers = 64) 
vs. PBO ( n = 133, 
completers = 38) 
- Time to recurrence of any 
mood episode: Ari > PBO 
- Rates of recurrences of 
any mood episode: 
Ari < PBO 
- Effects observed 
predominantly on manic 
episodes 
3 a 
Chan et al. 
(2016) 
Open RIS-LAI mirror 
(BD-I) pre- and post-1 
year RIS-LAI 
469 (1; N) 12 months RIS-LAI + TAU (2 
groups, compliant 
and non-compliant 
n = 77) vs. 




n = 392) 
- Re-hospitalization rates 
were significantly lower in 
the post RIS-LAI1 group than 
pre-RIS-LAI period for any 
mood episode, manic and 
depressive episodes 
- Rates of emergency room 
visit were significantly 
lower in the RIS-LAI1, 
RIS-LAI2 and NRIS-LAI1 
groups compared with those 
before enrollment 
2 
Fu et al. 
(2015) 
DB Pal-P vs . PBO surv 
(SAD) 
334 (84, 8 
countries in 4 
continents; Y) 
15 months Pal-P once 
monthly + TAU or 
monotherapy (SAD 
n = 164) vs. 
PBO + TAU (SAD 
n = 170) 
- Time to relapse for 
psychotic, depressive, and 
manic symptoms: Pal-P in 
add-on or 
monotherapy > PBO 
- Overall relapses rates: 
Pal-P in add-on or 
monotherapy < PBO 
- Relapse risk: 2.49 times 
greater for PBO than for 
Pal-P 
3 
Vieta et al. 
(2012) 
DB RIS-LAI vs . PBO 
surv (BD-I) 
398 (34 in 4 
continents; Y) 
18 months RIS-LAI (22, 37.5 
or 50 mg/2 weeks, 
n = 132) vs. PBO 
( n = 135) vs. third 
arm Ola (10 mg/d) 
( n = 131) 
- Time to recurrence of any 
mood episode: RIS-LAI > PBO 
- Time to recurrence of 
manic episodes: 
RIS-LAI > PBO 
- Time to recurrence of 
depressive episodes: 
RIS-LAI = PBO 
3 a 
( continued on next page ) 
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Table 1 ( continued ) 
Studies by first 
author and 
date in reverse 
order 
Study design Population, n 
(sites; sp. Y/N) 
Duration Drug Main outcomes Quality 
(includes 
bias) 
Bobo et al. 
(2011) 
Open, randomized 
RIS-LAI (BD-I and II 
rapid cycling) 
50 (1; Y) 12 months RIS-LAI + TAU 
( n = 25) vs. TAU 
( n = 25) 
Rates of any-cause relapse 
events: RIS-LAI + TAU = TAU 
Duration of relapse events 
(any cause): 
RIS-LAI + TAU = TAU 
3–4 
Chengappa 
et al. (2010) 
Open, randomized 
RIS-LAI vs . oral (BD-I 
and II) 
48 (3; Y) 15 months RIS-LAI (25, 37.5 
or 50 mg/2 
weeks) + TAU 
(n = 25) vs. SGA 
(Ari, Ola, Que 
Zip) + TAU 
(n = 25) 
Number of negative clinical 
events: RIS-LAI + TAU < 
SGA + TAU 
3 
Quiroz et al. 
(2010) 
DB RIS-LAI vs . PBO, 
surv (BD-I) 
303 (57, 10 
countries in 3 
continents; Y) 
24 months RIS-LAI (12.5, 25 
37.5 or 50 mg/2 
weeks) ( n = 154) 
vs . PBO ( n = 149) 
Time to recurrence: 
RIS-LAI > PBO (significant 
differences for elevated 
mood episodes but no for 
depressive episodes) 
2 
Peuskens et al. 
(2010) 
Open RIS-LAI discont. 
SAD vs . schizophrenia 
1659 (6 
nationwide 
databases in 2 
continents; Y) 




(SDA n = 171) vs 
RIS-LAI 
discontinuers after 
2 years (mean 
dose: 48.8 mg/2 
weeks) (SDA 
n = 32) 
Compared to the pre-RLAI 
initiation period, at 12 
months post-initiation 
completers had greater 
reductions than 
discontinuers in the percent 
of patients hospitalized and 
in the length and number of 
hospital stays, differences 




et al. (2009) 
DB add-on RIS-LAI 
(BD-I and II) 
124 (32, 2 
countries from 
2 continents; Y) 
12 months RIS-LAI (25, 37.5 
or 50 mg/2 
weeks) + TAU 
( n = 65) vs 
PBO + TAU 
( n = 59) 
Time to recurrence: 
RIS-LAI + TAU > PBO + TAU 
3 
Vieta et al. 
(2008) 
Open mirror RIS-LAI 
(BD-I) 
29 (1; N) 24 months 
(mean) 
RIS- 
LAI + TAU( n = 29) 
(mean starting 
dose = 34.4 mg, 
mean final 
dose = 46.4 mg) 
- Decreased number of 
hospitalizations (not due to 
depression) 
- Decreased average length 
of hospitalizations per 
patient 
- Increased time to any 
relapse 
- Improvement in treatment 
adherence 
2–3 
Yatham et al. 
(2007) 
Open, randomized 
RIS-LAI (BD I and II) 
49 (8 in 1 
country; Y) 
6 months RIS-LAI 
(25 mg/2weeks) 
+ TAU ( n = 23) vs. 
SGA (Ola, Que, 
Ris) + TAU ( n = 26) 
CGI-S, YMRS and MADRS: 
RIS-LAI + TAU = SGA + TAU 
2–3 
( continued on next page ) 
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Table 1 ( continued ) 
Studies by first 
author and 
date in reverse 
order 
Study design Population, n 
(sites; sp. Y/N) 
Duration Drug Main outcomes Quality 
(includes 
bias) 
Savas et al. 
(2006) 
Open mirror RIS-LAI 
(BD-I) 
12 (1; N) 6 months RIS-LAI + TAU or 
RIS-LAI 
monotherapy 
( n = 12) 
(25–50 mg/2 
weeks) 
- RIS-LAI significantly 
reduced the severity of 
symptoms, and no manic or 
depressive episodes were 
seen in these previously 
noncompliant patients in 
6-month period 
4 
Esparon et al. 
(1986) 
DB Flup-D (BD-I) 11 (1; N) 12 months Flup-D (20 mg/4 
weeks + Li 
(0.6–1.2 mEq/L) 
( n = 9) vs Li + PBO 
( n = 6) 
- Total number of days spent 
in hospital: 
Flup-D + Li = Flup-D + PBO 
- Effects in the prophylaxis 
of either mania or of 
depression: 
Flup-D + Li = Flup-D + PBO 
4 




204 (31, 5 
countries in 1 
continent; Y) 
18 months Flup-D (20 mg/3 
weeks) ( n = 19) vs 
Lithium (0.8–1 
MEq/L) ( n = 14) 
Group I : Mean episode 
frequency: Flup-D = Li 
Mean%time ill: Flup-D = Li 
3 
a High discontinuation/low completer rate. Abbreviations: Ari, aripiprazole; Ari-M, aripiprazole monohydrate; BD, bipolar disorder 
(-I. type I; -II, type II); DB, double-blind study; CGI-S, Clinical Global Impression-Severity; discont., discontinuation as outcome; Flup-D, 
flupenthixol decanoate; Li, lithium; MADRS, Montgomery Asberg Depression Rating Scale; n , number; N, no; Ola, olanzapine; Open, open- 
label study; Pal-P, Paliperidone palmitate; PBO, placebo; Que, quetiapine; RIS-LAI, risperidone long-acting injectable; SAD, schizoaffective 
disorder; SGA, second generation antipsychotic; sp. Y/N, industry-sponsored, Yes/No; surv, survival study (Kaplan-Meyer estimates); TAU, 
treatment-as-usual; Y, yes; YMRS, Young Mania Rating Scale; Zip, ziprasidone. Quality assessment: 1, first rate evidence; 2, good evidence; 





















































ifferences were found between flupenthixol and PBO in the 
verage number of days hospitalized during the depot pe- 
iod. When total scores were calculated on the Affective 
orbidity Index, ratings for depression were worse for the 
upenthixol group, although this result was not statistically 
ignificant. 
.2.2. Second-generation depot antipsychotics (SGDA) 
e identified eleven clinical studies that investigated RIS- 
AI in BD or SAD patients, 1 investigating Pal-P and 1 Ari-M.
hese included 8 open label prospective or mirror studies 
nd 5 RCT. 
Open-Label studies and unblinded controlled trials. 
avas et al. (2006) examined the charts of 12 BDI predomi-
antly manic patients, with no substance abuse and nonad- 
erent to oral medication who received RIS-LAI 25–50 mg/2 
eeks started during a manic or hypomanic state during 
 months either in monotherapy or in combination with a 
ood stabilizer. No manic or depressive episodes were ob- 
erved during depot treatment. A significant reduction in 
linical Gobal Impression Scale (CGI) was found, while there 
ere no changes in Hamilton Depression Rating Scale (HAM- 
) scores. 
An open, randomized active comparator trial with RIS-LAI 
s. oral atypical antipsychotic agents (AAP) was reported 
y Yatham et al. (2007) in BD I or II patients currently on
ne oral SGA who had Young Mania Rating Scale (YMRS)Please cite this article as: I. Pacchiarotti, J. Tiihonen and G.D. Ko
maintenance treatment of bipolar and schizoaffective disorders: A 
//doi.org/10.1016/j.euroneuro.2019.02.003 nd Montgomery-Asberg Depression Rating Scale (MADRS) 
etween 13 and 19 and CGI scores between 3 and 4 (mildly
o moderately ill). Patients were randomized to receive RIS-
AI 25–50 mg/2 weeks or to continue previous oral SGA dur-
ng 6 months. Mood stabilizers and antidepressants were 
ermitted. Patients on RIS-LAI but not those on oral SGAs
mproved significantly in CGI-S and YMRS scores at 6-month
ollow-up. In contrast the oral SGA group had significant re-
uctions in Hamilton Anxiety Rating Scale (HAM-A) scores 
elative to baseline compared to BD patient treated with
IS-LAI. 
Vieta et al. (2008) assessed 29 acutely manic BDI patients
ho had one or more previous hospitalisations for mania
nd with a history of non-adherence to medication in a
aturalistic two-year follow-up study. Patients received 25–
0 mg/2 weeks of RIS-LAI plus a mood stabilizer and other
ommonly prescribed medication but no other oral antipsy- 
hotics were allowed. Outcomes were compared with a 
revious period of one year before initiating RIS-LAI. The
uthors found a significant reduction in treatment discon- 
inuation, a decrease in the number of hospitalizations per
atients, a significant decrease in hospitalisations for mania 
r mixed episodes with RIS-LAI. No significant decreases in
ospitalization rates for depression were found. Moreover, 
he mean length of stay per patient significantly decreased
nd time to relapse to any mood episode increased. Finally,
mproved CGI scores and decreased aggression were found 
ith RIS-LAI. tzalidis et al., Long-acting injectable antipsychotics (LAIs) for 
systematic review, European Neuropsychopharmacology, https: 
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Peuskens et al. (2010) assessed treatment retention ( vs.
discontinuation) on RIS-LAI and outcomes in schizophrenia
and SAD patients for whom 24 months of follow-up data in
the electronic Schizophrenia Treatment Adherence Registry
(e-STAR) were available. 
Data were available for 171 RIS-LAI completer vs . 32 RIS-
LAI discontinuer SAD patients. Compared to the pre-RLAI ini-
tiation period, at 12 months post-initiation completers had
greater reductions than discontinuers in the percent of pa-
tients hospitalised (66.2% reduction vs . 29.2%) and in the
length (68% reduction vs . 0%) and number (80.0 vs . 14.3%)
of hospital stays, differences that remained unaltered after
24 months. 
In a randomised, but open-label, 15-month pilot trial
assessing clinical effectiveness, Chengappa et al. (2010) as-
sessed the efficacy of RIS-LAI compared to oral SGAs in BD-I
or -II during a manic, hypomanic or mixed episode. The
study provided for a 3-month titration and stabilization
phase followed by a 1-year extension phase. The results of
the study showed that RLAI-treated patients experienced
significantly fewer negative clinical events (47 negative
clinical events were recorded in terms of outcome and
other safety measures) than AAP-treated patients. 
Bobo et al. (2011) compared adjunctive RIS-LAI plus
treatment as usual (RLAI + TAU) in a 12-month randomised
open comparison of RLAI + TAU ( N = 20) and TAU alone
( N = 25) in BD-I or -II with rapid cycling course. The results
showed no significant between-groups differences in the to-
tal number or duration of relapse events (any cause) or in
the number of manic or depressive relapses. RIS-LAI treat-
ment significantly reduced the need for urgent care refer-
rals or the frequency of medication adjustments to prevent
relapses. 
In a retrospective cohort study, Chan et al. (2016) as-
sessed the effect of RIS-LAI treatment on BDI patients
treated with RIS-LAI and different oral SGAs and followed
during 1 year. On the basis of RIS-LAI use and treatment
compliance, BD patients were classified into 4 groups:
compliant patients receiving RIS-LAI treatment (LAI1),
noncompliant patients receiving RIS-LAI treatment (LAI2),
compliant patients receiving oral medications (NLAI1) and
noncompliant patients receiving oral medication (NLAI2).
After 1-year of follow-up, re-hospitalization rates were
significantly lower in the LAI1 group than that before
enrolment for any episode (manic episodes ( p = 0.005);
depressive episodes ( p = 0.002). Emergency room visit
rates were significantly lower in the LAI1 ( p = 0.0001), LAI2
( p = 0.013), and NLAI1 ( p = 0.0001) groups, compared to
the respective pre-enrolment rates. 
Recently, a 1-year mirror-image naturalistic study using
a national claims database ( Hsieh et al., 2017 ) assessed
RIS-LAI treatment in BD patients. Rapid and non-rapid cy-
cling stratification was performed based on the number of
change-in-mood episodes within 1 year prior to the index
date. The authors found that the prevalence of concomi-
tant use of TAU decreased from the pre-RIS-LAI period to
the post-RIS-LAI period. RIS-LAI use decreased emergency
room (ER) visits, hospital admissions, length of hospital stay,
and non-medication costs. Moreover, RIS-LAI use decreased
the number of change-in-mood episodes in rapid cycling
patients. Please cite this article as: I. Pacchiarotti, J. Tiihonen and G.D. Ko
maintenance treatment of bipolar and schizoaffective disorders: A 
//doi.org/10.1016/j.euroneuro.2019.02.003 Double-blind, randomised PBO-controlled trials.
MacFadden et al. (2009) reported the results of a double-
blind randomised, PBO-controlled trial with RIS-LAI 25–
50 mg/2week as adjunctive treatment to TAU in frequently
relapsing BDI patients (who had experienced 4 or more
episodes during the past year). Patients were stabilized in a
16-week open-label phase with RIS-LAI and then randomised
to continue RIS-LAI ( n = 65) or switch to PBO ( n = 59). Both
groups continued with TAU, which included mood stabi-
lizers and other medications, but not oral antipsychotics.
The results showed that the relative risk of relapse was
2.3-fold higher with PBO compared with RIS-LAI group. A
significant delay in time to recurrence to any mood episode
was observed with RIS-LAI. Moreover, a significant increase
in YMRS scores and CGI-BP-S mania and overall scores
was found in the RIS-LAI group compared with PBO, while
no differences were found in MADRS scores and CGI-BP-S
depression between the two groups. 
A 24-month randomised, double-blind, PBO-controlled
study with RIS-LAI in monotherapy was conducted by Quiroz
et al. (2010) on acute manic/mixed (YMRS ≥ 20) or stable
(CGI-S score ≤3) BD-I patients, but requiring change of med-
ication to depot due to safety or tolerability concerns. Pa-
tients were excluded from the study if they had more than
4 episodes/year in the 2 years before the screening (rapid
cycling). BD-I patients started on the 26-week open-label
stabilization phase with RIS-LAI. During the randomisation
phase, 154 patients received RIS-LAI 25–50 mg/2 weeks and
149 PBO, with a follow-up of 24-months. Results showed
a significant delay in time to relapse in the RIS-LAI group
compared to PBO for any mood episode ( p < 0.001) and
lower rates of recurrence with RIS-LAI (30% with RIS-LAI vs .
56% with PBO). RIS-LAI significantly prolonged time to dis-
continuation for any reason compared to PBO. Nonetheless,
time to recurrence was longer for RIS-LAI group compared
with PBO group only for manic/hypomanic episodes but not
for depressive episodes. RIS-LAI was significantly superior in
maintaining the YMRS, MADRS, and CGI-S scores than PBO. 
Later, the efficacy of RIS-LAI for preventing recurrence
of mood episodes in BD-I patients was evaluated in another
randomized, PBO-controlled study ( Vieta et al., 2012 ).
After a 12-week open-label stabilization period with RIS-LAI
( N = 560), patients who did not experience a recurrence
entered an 18-month randomised, double-blind period
with RIS-LAI ( N = 132), PBO ( N = 135) or with olanzapine
10 mg/day ( N = 131) as third treatment arm for reference
and exploratory comparisons. Time to recurrence of any
mood episode was significantly longer with RIS- LAI vs. PBO
(log-rank test stratified by region only, p = 0.031). Similarly
to previous studies, differences were significant for time
to recurrence of manic/hypomanic episodes ( p = 0.005) but
not depressive episodes ( p = 0.655). 
Regarding the efficacy of paliperidone palmitate (Pal-P)
the only study included is a double-blind, PBO-controlled
trial on SAD patients ( Fu et al., 2015 ). SAD patients expe-
riencing acute psychotic and depressive/manic symptoms
were stabilized with Pal-P monthly as monotherapy or as
adjunctive therapy to mood stabilizers or antidepressants.
After an open-label stabilization period of a 13-week,
flexible-dose and of a 12-week fixed-dose, patients and ran-
domly assigned to Pal-P monthly ( N = 164) or PBO ( N = 170)tzalidis et al., Long-acting injectable antipsychotics (LAIs) for 
systematic review, European Neuropsychopharmacology, https: 
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n a 15-month, double-blind, relapse-prevention phase. Pal- 
 significantly delayed time to relapse for psychotic, depres- 
ive, and manic symptoms compared with PBO ( p < 0.001,
og-rank test). Relapse risk was 2.49 times greater for PBO 
hazard ratio = 2.49; 95% CI, 1.55 to 3.99; p < 0.001). More-
ver, Pal-P was superior to PBO in maintaining functioning 
s measured by the Personal and Social Performance scale 
 p = 0.014, mixed-model repeated-measures analysis). 
Recently, Calabrese et al. (2017) reported the results of 
 52-weeks, randomized, double-blind, PBO-controlled trial 
n the efficacy of aripiprazole monohydrate depot (Ari-M) 
00 mg once-monthly as maintenance treatment of BD-I. 
D-I patients experiencing a manic episode were stabilized 
equentially on oral aripiprazole and Ari-M 400 mg (18–26 
eeks) and then were randomised to Ari-M 400 mg ( N = 133)
r PBO ( N = 133) during a 52-week follow-up period. 64 pa-
ients on Ari-M and 38 patients on PBO completed the study.
ri-M 400 significantly delayed time to recurrence of any 
ood episode compared with PBO ( p < 0.0001). Signifi-
antly fewer patients ( p < 0.0001) experienced recurrence 
f any mood episode with Ari-M 400 (35/132; 26.5%) com- 
ared with PBO (68/133; 51.1%), with stronger effects on 
anic episodes ( p < 0.0001). 
. Discussion 
e here performed a systematic review of the efficacy of
AI treatments in BD and SA; we rated our review according
o the AMSTAR system and we found it to be of moderate
uality ( Shea et al., 2017 ). The present systematic review
xamined the efficacy of LAIs for maintenance treatment of 
D and SAD compared with PBO and oral medications. Re-
arding FGDAs, although there are not head-to-head com- 
arisons between FGDAs and SGDAs, the trials reviewed in- 
icate that there are some differences between these two 
P groups. Depot Flup-D was the AP most investigated. 
here are only two controlled studies and they are negative.
he PBO controlled study with Flup-D added to lithium and 
he comparison of Flup-D vs . lithium did not show differ-
nces in days of hospitalization, number of episodes/year 
nd time spent ill ( Ahlfors et al., 1981; Esparon et al.,
986 ). Moreover, the negative results of Esparon’s et al. ran-
omized trial (1986) might be due to the lack of effect on
epression or a possible worsening of depression with Flup- 
 compared to PBO, even if the more severe depression 
ound in six of eight Flup-D-treated patients was not sta- 
istically significant. Overall, FGDAs might be as effective 
s lithium in preventing manic episodes, but without effi- 
acy on depressive recurrences, and they might even worsen 
epressive symptoms. Limitations of FGDA studies include 
he lack of adequate sample sizes, comparators arms and 
utcome measures for mood disorders. Furthermore, their 
ime-frame is different from those carried-out on SGDAs 
nd this may impact multiple factors that might affect out-
omes, including diagnostic modalities and study designs. 
With respect to SGDAs, the most robust evidence is re-
ated to the use of RIS-LAI depot. RIS-LAI was found to be
ffective in preventing relapses of any mood symptoms (pri- 
ary outcome) as well as for preventing manic symptoms 
ompared to PBO, including BD patients with rapid cycling in 
hom RIS-LAI resulted more effective compared also to oral Please cite this article as: I. Pacchiarotti, J. Tiihonen and G.D. Ko
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//doi.org/10.1016/j.euroneuro.2019.02.003 edications ( Macfadden et al., 2009; Martinez-Aran et al.,
009; Kishi et al., 2016 ). 
Furthermore, the use of RIS-LAI improved CGI-S ( Savas
t al., 2006; Yatham et al., 2007; Vieta et al., 2008; Mac-
adden et al., 2009; Vieta et al., 2012 ) and YMRS scores
 Yatham et al., 2007; Macfadden et al., 2009; Quiroz et al.,
010 ), decreased number of hospitalisations and the length
f stay ( Vieta et al., 2008, 2012; Peuskens et al., 2010;
sieh et al., 2017 ), and reduced discontinuation rates of
urrent treatments ( Vieta et al., 2008; Quiroz et al., 2010 )
nd hetero-aggressive episodes ( Vieta et al., 2008 ). When
he study was observational and other drugs could be used
long RIS-LAI, ( Vieta et al., 2008 ), about one third of pa-
ients were receiving or introduced lithium, while all pa-
ients were on anticonvulsants or lithium throughout the 
tudy; this could have affected outcome, hence studies are
eeded to evaluate the ability of each treatment alone or
ombined in preventing a bipolar mood episode. 
Although RIS-LAI did not show an efficacy in prevent-
ng depressive recurrences, at the same time this drug did
ot worsen depressive symptoms as did the FGDAs ( Esparon
t al., 1986; Macfadden et al., 2009; Hsieh et al., 2017 ). 
The only study assessing the efficacy of Pal-P in SAD
atients showed the efficacy of this drug in preventing
sychotic, depressive, and manic symptoms both in add-on 
r monotherapy and in improving and maintaining func- 
ioning beyond symptom control ( Fu et al., 2015 ). Further
tudies are needed to assess the efficacy of Pal-P in the
aintenance treatment of BD, both in terms of manic and
epressive relapses. 
Similarly, the results of the study of Calabrese et al.,
2017) investigating the efficacy of Ari-M in BD patients gave
upport to the FDA indication of this drug for the mainte-
ance treatment of BD-I. In fact, in patients with BD-I who
ad a manic episode at study enrolment, Ari-M delayed the
ime to mood episode recurrence (primarily manic), without 
ncreasing depressive episodes. 
Noteworthy, the predominantly antimanic vs. antidepres- 
ant preventive efficacy of LAIs in BD is consistent with their
olarity index ( Popovic et al., 2012 ) and with their use in
atients with poor treatment adherence. In fact, several 
tudies found that factors that have been related with poor
dherence in BD and SAD include a rapid cycling course, a
reater illness severity ( Martinez-Aran et al., 2009; Perlis
t al., 2010 ), the predominance of manic symptoms and a
igher rate of recurrences and hospitalisations, but not de-
ressive symptoms ( Sylvia et al., 2014 ). In this sense, LAIs
ay represent an effective treatment strategy by increas- 
ng medication adherence and by reducing relapses in these
ubtypes of BD patients. To test the ability of LAI medi-
ations to supersede their oral counterparts in preventing 
ood episodes, study designs should focus on accurately as-
essing treatment adherence and clinical course in parallel 
roups receiving the same drug, one oral and the other LAI.
.1. Limitations 
he limitations of this review are the same of the studies
t included, and include undisclosed intersite differences 
or the multisite trials, small sample sizes for the older LAI
rials, inconsistent methodologies that prevented us from tzalidis et al., Long-acting injectable antipsychotics (LAIs) for 
systematic review, European Neuropsychopharmacology, https: 
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Table 2 Tentative indications for BD and SAD maintenance treatment with LAIs. 
Patients at risk of stopping medication on their own: 
With a severe, psychotic manic episode 
With a history of relapse after discontinuation of antipsychotic medication 
With predominantly manic episodes or manic predominant polarity 
Who responded partially or who are fully refractory to conventional mood-stabilizers 
With schizoaffective disorder, bipolar type 
With a rapid cycling course 
Showing good tolerability to oral aps 
APs, antipsychotic drugs; BD, bipolar disorder; LAIs, long-acting injectable antipsychotic drugs; SAD, schizoaffective disorder. 
Table 3 Take-home messages for LAIs used in BD and SAD. 
LAI drugs Take-home message Specific effects Side effects 
Risperidone microspheres Needs to be administered 
twice as often as paliperidone 
palmitate 
Effective as antipsychotic, 




extrapyramidal side effects 
Olanzapine pamoate Gradually abandoned; Possible 
advantage: May facilitate 
antidepressant actions of ADs a 
Effective as antipsychotic, 
highly selective on D 2 receptors 
Post-injection syndrome; 
injection site reaction 
frequent; metabolic 
syndrome; obesity 
Paliperidone palmitate Tested in SAD, not in BD; may 
be less indicated for people 
with SUD b ; Possible advantage: 
Multiple dosages available 
Effective as antipsychotic, 




extrapyramidal side effects 
Aripiprazole monohydrate Advantages: Effective in BD; 
large effects on QoL b ; 
Disadvantage: Needs oral 
supplementation at initiation 
Allows better prefrontal 
function thanks to partial 
agonism on D 2 receptors 
Akathisia 
Aripiprazole lauroxil Not yet tested in BD or 
specifically in SAD; Possible 
advantage: Longer intervals of 
administration, multiple dosing 
Allows better prefrontal 
function thanks to partial 
agonism on D 2 receptors 
Akathisia 
ADs, antidepressants; BD, bipolar disorder; LAIs, long-acting injectable antipsychotic drugs; QoL, quality of life; SAD, schizoaffective 
disorder. 
a Tohen et al. (2003) . 







































performing a meta-analysis, and generally medium level of
evidence. A comparison between LAIs and first generation
depot neuroleptics is not feasible, since the older published
studies lacked scientific rigour. 
Summarizing, the level of evidence for the use of LAIs in
the maintenance treatment of BD and SAD is still limited,
since there are only a few large, controlled, randomised tri-
als in the literature, but there are several clinical scenarios
in which they may be a first-line option, with the exception
of FGDAs, due to the risk of inducing depression. Examin-
ing the use of SGDAs, evidence reviewed on RIS-LAI suggests
that this drug is effective as maintenance treatment in BD
and SAD and in improving adherence to medication in these
patients, through the efficacy on manic recurrences, with-
out worsening depression. Similarly promising results have
been found with Pal-P in SAD patients and with Ari-M in BD
patients. Tentative indications for the use of LAIs in BD and
SAD are shown in Table 2 . 
Further studies are needed on the use of LAIs in BD
and SAD, especially assessing the newest drugs such asPlease cite this article as: I. Pacchiarotti, J. Tiihonen and G.D. Ko
maintenance treatment of bipolar and schizoaffective disorders: A 
//doi.org/10.1016/j.euroneuro.2019.02.003 paliperidone and aripiprazole in special populations of BD
patients, i.e. those with rapid cycling or with high numbers
of manic relapses, in order to improve treatment adher-
ence and the clinical course of BD. Moreover, the long-term
impact of those compounds on cognitive and functional
outcomes, which are heavily influenced by the number of
manic recurrences ( Sanchez-Moreno et al., 2018 ), should be
addressed. Future studies should also focus on site of injec-
tion (deltoid vs . gluteal) ( Heres et al., 2012 ) and timing of
administration (twice vs . once-monthly vs . three-month),
as well as on less invasive methods of drug level monitoring
( Murru et al., 2017 ). 3-Month paliperidone has advantages
and disadvantages over once-monthly injections, and so
may prove to have aripiprazole lauroxil with its two-month
option, although it has not as yet been tested in BD. We
await studies with these novel LAI formulations to gain a
complete picture of LAIs in the treatment of BD and SAD.
Furthermore, the concomitant use of LAI antipsychotics
and mood stabilizers should be adequately assessed like in
Macfadden et al. (2009) , as there is preliminary evidencetzalidis et al., Long-acting injectable antipsychotics (LAIs) for 
systematic review, European Neuropsychopharmacology, https: 
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hat oral SGA antipsychotic add-on might protect against 
anic relapses/recurrences in BD. 
Another issue needing clarification is whether side effects 
elated to LAIs tend to be “long-acting” as their formula- 
ion. There always has been concern among clinicians as 
o this aspect, but reassuring data as to the similarity with
he side effects observed with oral antipsychotics has been 
athered over the years, with patients gradually adapting to 
hese side effects ( Knudsen et al., 1985; Marder, 1986 ). Al-
hough in one study LAIs compared favourably to their oral
ounterparts for what concerns side effects ( Sa ̆glam Aykut 
t al., 2017 ), there are still concerns regarding their dos-
ng and availability ( Taylor, 2009 ), as well as suicide risk
 Gentile, 2013 ), that should be addressed by future studies.
In conclusion, we provide a take-home series of mes- 
ages in Table 3 , including each LAI’s specific actions and
ide effects that may limit their application in patients with
ipolar or schizoaffective disorder. 
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